Chemotherapy Strategies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Eileen O’Reilly, MD
Efrat Dotan, MD
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)
Fernando López-Ríos, MD, PhD
Christian Rolfo, MD, PhD
Charlie Gourley, MD, PhD
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
Fortunato Ciardiello, MD, PhD
Jenny Seligmann, MBChB, PhD
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
Mastering Mutation-Driven mCRC: From Testing to Targeted Therapy
Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management
Elizabeth R. Plimack, MD, MS, FASCO
Shilpa Gupta, MD
Reviewing the Latest Bladder Cancer Practice Guidelines
Exploring New and Emerging Treatments in Muscle Invasive Bladder Cancer
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC): From Diagnosis to Treatment
Shubham Pant, MD, MBBS
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
Peter Schmid, FRCP, MD, PhD
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
Sara Lonardi, MD
The Evolving Treatment Landscape for MBC: Emerging Therapies
William J. Gradishar, MD
Emerging Treatment Approaches for EBC
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
Erica L. Mayer, MD, MPH
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.